Progress of the role of sclerostin in metabolic diseases

VernacularTitle:硬骨抑素在代谢性疾病中的研究进展
Author: Tingting XING ¹ ; Yan LI ; Luona WEN ; Chunlei LI ; Yan LIU ; Xiaoshi ZHONG ; Rongshao TAN
Author Information

1. 暨南大学附属广州红十字会医院临床病态营养研究所，广州　510220
Keywords: Sclerostin; Lipid metabolism; Glucose metabolism; Obesity; Diabetes
From: Chinese Journal of Endocrinology and Metabolism 2024;40(2):168-172
CountryChina
Language:Chinese
Abstract: Lipid and glucose metabolism play crucial roles in maintaining energy homeostasis, and their dysregulation can lead to the development of metabolic disorders, such as obesity and diabetes. Studies indicate that the skeleton, involved in lipid and glucose metabolism, functions as an endocrine organ, regulating systemic metabolism through bone-derived molecules. Sclerostin is a protein mainly produced by osteocytes, possessing the ability to inhibit bone formation, and its antibodies have become therapeutic targets for treating osteoporosis. Recent evidence suggests that sclerostin also plays a role in lipid and glucose metabolism disorders. Therefore, through summarizing in vitro and in vivo researches, this article reviews the role of sclerostin in lipid and glucose metabolism, its relationship with obesity and diabetes, and potential role in the treatment of metabolic diseases in the future.